Work

Supplementary Data from Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Year: 2023

Type: supplementary-materials

DOI: 10.1158/1078-0432.22479924

Authors: Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani

Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University Hospital Münster, Pfizer (United States), Navigate BioPharma (United States), Pfizer (Germany), Cleveland Clinic

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361939098

Cites:

Cited by:

Related to: 10